{"title": "Pat-INFORMED Participants", "author": null, "url": "https://www.wipo.int/pat-informed/en/participants/index.html", "hostname": "wipo.int", "description": "List of participant companies in the Pat-INFORMED Initiative.", "sitename": "WIPO", "date": "2016-01-01", "cleaned_text": "that comes up with new approaches to addressing today's health issues - from life-threatening illness to chronic conditions. The company is especially focused on discovering, developing and delivering drugs in therapeutic areas like: immunology, oncology, neuroscience, virology and general medicine. Astellas is a pharmaceutical company focused on providing innovative medicines; its priority areas for research & development are infectious diseases, diabetes, gastrointestinal diseases, oncology and diseases of the central nervous system. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. Bristol-Myers Squibb is a global biopharmaceutical company focused on helping to address the unmet medical needs of patients with serious diseases. The company focuses its R&D in oncology, cardiovascular, immunoscience, and fibrosis, in addition to drug discovery plaforms. Daiichi Sankyo is a global pharmaceutical company, with over 100 years of scientific expertise, that research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. Eisai defines its corporate mission as \"giving first thought to patients and their families and to increasing the benefits health care provides,\" which the firm calls its human health care (hhc) philosophy. Eisai strives to realize this philosophy by delivering innovative products to address unmet medical needs, with a particular focus in the strategic areas of Oncology and Neurology. Gilead Sciences Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Its portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK is currently focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation; with an R&D approach focused on science related to the immune system, use of genetics and advanced technologies. Ipsen is a biopharmaceutical company that is developing innovative therapies in oncology, neuroscience and rare diseases. Ipsen has a leading-edge technological platform in toxins that offers potential in the treatment of neuromuscular disorders, as well as for pain and aesthetic medicine. Johnson & Johnson is the world's largest and most broadly based healthcare company. Its pharmaceutical companies are actively developing treatments for patients in six important therapeutic areas: cardiovascular and metabolism, immunology, neuroscience, infection disease and vaccines, oncology, and pulmonary hypertension. The firm strives to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone. LEO Pharma is an independent, research-based pharmaceutical company that develops, manufactures and markets dermatologic and thrombotic pharmaceutical drugs in more than 100 countries globally. The company's current research & development focuses on actinic keratosis, eczema, inflammatory indicators, psoriasis and acne. Lilly is a global pharmaceutical company which conducted research in more than 55 countries, and has its products marketed in 120 countries worldwide. Lilly is currently the largest manufacturer of psychiatric medications. Merck is a science and technology company in healthcare, life science and performance materials. The company designs and develops medicines and intelligent devices, including new medication to treat conditions such as cancer or multiple sclerosis. The company's therapeutic business areas are: allergies, endocrinology, fertility, oncology, and neurodegenerative diseases. MSD is a pharmaceutical company that focuses on developing and manufacturing medicine in areas such as: antimicrobial resistance, diabetes, hepatitis C, HIV, oncology, cardiovascular, sleep disorder, vaccines, as well as animal health. Novartis is a biopharmaceutical company that aims to deliver innovative medicines globally. areas are: oncology, cardio-metabolic, immunology, dermatology, ophthalmology, neuroscience and respiratory diseases. Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. The company's focus areas are obesity, hemophilia, growth disorders and other serious chronic diseases. Pfizer is a biopharmaceutical company that strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Pfizer's global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products, and focuses its R&D projects in therapeutic areas such as: internal medicine, rare disease, inflammation & immunology, vaccines, oncology and new R&D platforms focused on gene therapy, precision medicine and biosimilars. Roche is a biotechnology company with an R&D focus on: oncology, neuroscience, immunology, cardiovascular and metabolism, research technologies, ophthalmology, haematology, respiratory, women's health and infectious diseases. Shionogi is a global pharmaceutical company that develops and commercializes products to treat unmet medical needs relating to infectious diseases and pain management, as well as other areas such as chronic liver disease. The company is also pursuing development of new treatments in inflammatory pain, neuropathic pain, Alzheimer's disease, and ADHD. Takeda is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda stays at the leading edge of innovation, focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions. The company also builds on scientific advances and skills in genetics, biomarkers and human biology. "}